Home / Health / Elicio Therapeutics to Present at Wells Fargo Conference
Elicio Therapeutics to Present at Wells Fargo Conference
24 Aug
Summary
- Elicio Therapeutics will present at the Wells Fargo Healthcare Conference.
- The company focuses on immunotherapies for KRAS-driven cancers.
- Their lead program targets common KRAS mutations in solid tumors.
Elicio Therapeutics, Inc., a clinical-stage biotechnology firm, will have its management team present at the upcoming Wells Fargo 21st Annual Healthcare Conference. The conference is scheduled to take place from September 8-10, 2026, in Boston, Massachusetts.
Elicio Therapeutics specializes in developing next-generation immunotherapies for KRAS-driven cancers. Their core focus includes treating KRAS-positive pancreatic and colorectal cancers by advancing off-the-shelf immunotherapies. The company's proprietary AMP technology is designed to enhance T-cell responses against cancer.
The company's lead candidate, ELI-002 7P, targets the most prevalent KRAS mutations, which are implicated in about 25% of all solid tumors. Elicio is also developing other candidates targeting BRAF-driven cancers and p53 hotspot mutations.
Interested parties wishing to schedule a one-on-one meeting with Elicio's management during the conference should contact their Wells Fargo representative. The specific meeting date for Elicio's management is Thursday, September 10, 2026.
